The Vaccine Study Center (VSC) will develop a protocol, coordinate and lead Rapid Cycle Analysis activities to monitor the safety of COVID-19 vaccines in near real-time. Through near-real time monitoring the VSC will identify and investigate possible asso...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
To describe the safety and tolerability profiles of prophylactic BNT162 vaccines in healthy adults after 1 or 2 doses
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study will estimate influenza vaccine effectiveness by vaccine type and for different ages by combining data from medical records, vaccine registries, and results of clinician-ordered molecular tests for influenza virus infection at Kaiser Permanente...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
People with HIV are at increased risk for dementia due to the combined effects of HIV-associated inflammation and traditional (non-HIV) risk factors such as chronic drug use and cerebrovascular disease. With the widespread use of antiretroviral therapy fo...
Funder: Northern California Community Benefit Programs
Investigator: Lam, Jennifer
|
The risk of acute thrombotic events such as venous thromboembolism (VTE) and ischemic stroke in transgender women receiving hormone therapy was addressed in our longitudinal Study of Transition, Outcomes & Gender (STRONG), supported by the Patient-Centere...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
A phase 3, randomized, double-blind trial will evaluate the safety and immunogenicity of 3 lots of 20-valent Pneumococcal conjugate vaccine in Pneumococcal vaccine–naive adults 18 through 49 years of age. The purpose of this study is to evaluate the sa...
Funder: ICON Clinical Research PLC
Investigator: Klein, Nicola
|
This research will examine the relationship of alcohol use and depression over time using data based in the electronic health record (EHR), in the context of health care. We will conduct secondary analysis of depression and hazardous drinking patterns in ...
Funder: National Institute on Alcohol Abuse and Alcoholism
Investigator: Satre, Derek; Silverberg, Michael
|
The primary objective of this study is to evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events. Secondary objectives are:
1) To evaluate the anti-pneumococcal polysaccharide serotype-specific Imm...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Daniel; Klein, Nicola
|
The risk of acute thrombotic events such as venous thromboembolism (VTE) and ischemic stroke in transgender women receiving hormone therapy was addressed in our longitudinal Study of Transition, Outcomes and Gender (STRONG). STRONG is a cohort of transgen...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
This study employs a cluster randomization design to examine the vaccine effectiveness of Flublok relative to that of other flu vaccines used at Kaiser Permanente Northern California over two influenza seasons (2018 to 2019 and 2019 to 2020), in Kaiser Pe...
Funder: Protein Sciences Corporation
Investigator: Klein, Nicola
|
The purpose of this project is, first, to estimate the proportion of the population under study receiving one and two doses of recombinant zoster vaccine (RZV). Second, among live zoster vaccine (ZVL)-naive persons, this study aims to: 1) estimate the vac...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
This project will estimate Prevnar 13 (PCV13) vaccine effectiveness against invasive pneumococcal disease using a test-negative design in the Kaiser Permanente Northern California adult population from September 1, 2014, through December 31, 2017. Positiv...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study has three primary aims: 1) to estimate the relative vaccine effectiveness of Flucelvax versus inactivated influenza vaccine (IIV) in vaccinated Kaiser Permanente Northern California members aged 4 to 64 years against all PCR-confirmed influenza...
Funder: Shoo the Flu, LLC
Investigator: Klein, Nicola
|
Funder: ICON Clinical Research PLC
Investigator: Klein, Nicola
|
This is a phase IIIB, observer-blind, randomized, placebo-controlled, multi-center study to assess the safety and immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when administered concomitantly with routine vaccines ...
Funder: GlaxoSmithKline PLC
Investigator: Klein, Nicola
|
This project will identify all patients who have a laboratory-confirmed diagnosis of Hepatitis C. The intervention group will be those who had a prescription filled for a new antiviral medication after October 10, 2014, and who were naive to treatment for...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
Although the benefits of combination antiretroviral therapy (ART) for reducing HIV-related morbidity and mortality are well-recognized, toxicity from some ART may potentially contribute to excess age-related comorbidities. Certain antiretrovirals, includi...
Funder: Gilead Sciences, Inc.
Investigator: Silverberg, Michael
|
This project will identify all patients who have a laboratory-confirmed diagnosis of Hepatitis C. The intervention group will be those who had a prescription filled for a new antiviral medication after October 10, 2014, and who were naive to treatment for...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
This project has three major aims: 1) to examine whether influenza vaccination during pregnancy prevents influenza and other respiratory infections in infants aged 0 to 12 months, with a sub-aim to examine the effect of vaccine timing during pregnancy on ...
Funder: National Institute of Allergy and Infectious Diseases
Investigator: Zerbo, Ousseny
|
Kaiser Permanente Northern California has recently collaborated with Pfizer in identifying invasive and noninvasive group B streptococcus (GBS) disease burden in adults during a seven-year time period spanning 2007 to 2014. In Phase 1 of this research col...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study will investigate the safety of direct-acting antiviral medications in patients who have a laboratory-confirmed diagnosis of hepatitis C. The intervention group will be those who had a prescription filled for a new antiviral medication after Oct...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
The goal of this project is to determine the age-specific rates of laboratory-confirmed influenza-associated hospitalization among children, and to describe clinical and epidemiologic characteristics of pediatric hospitalized case-patients during the infl...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
The three objectives of this study are to: 1) Identify and compare the clinical, demographic and neighborhood characteristics associated with receipt of pneumococcal vaccine among persons 65 years of age and older, and among persons 18 to 64 years of age ...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
With support from the National Institute on Alcohol Abuse and Alcoholism, the Consortium to improve OutcoMes in HIV/Aids, Alcohol, Aging & multi-Substance (COMpAAAS) has analyzed data from patients in the Veterans Administration Cohort Study. This project...
Funder: National Institute on Alcohol Abuse and Alcoholism
Investigator: Satre, Derek; Silverberg, Michael
|
This study is a phase 3, randomized, active-controlled, observer-blinded study to assess the immunogenicity, safety, and tolerability of bivalent rLP2086 when administered as a two-dose regimen in healthy subjects 10 to 26 years of age. The project also i...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
|
